Omics Empower Hong Kong Launches Xenium™ In Situ Spatial Transcriptomics Services
HONG KONG, Feb. 13, 2026 /PRNewswire/ -- Omics Empower, a global life science service provider specializing in single-cell sequencing and spatial transcriptomics, announced that Xenium™ In Situ Spatial Transcriptomics services are now available at its Hong Kong Science Park laboratory. Since the launch of the Hong Kong laboratory in July 2025, Omics Empower has supported research teams with local...
Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for First Line Treatment of HER2-positive Breast Cancer
SAN FRANCISCO and SUZHOU, China, Feb. 13, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent",HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that the first participant has been successfully dosed in the pivotal Phase 3 clinical study (HeriCare-Breast01). The trial...
Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market...
- Comprehensive review of recent milestones highlights statistically significant efficacy in prostate cancer prevention, discovery of novel lipid-modulating properties, and the execution of high-value commercial partnerships in South Korea and Vietnam. NEW TAIPEI CITY, Feb. 13, 2026 /PRNewswire/ -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization...
SleepAI.com Introduces an AI-Powered Sleep and Emotional Wellness Platform for Modern Life
LOS ANGELES, Feb. 13, 2026 /PRNewswire/ -- SleepAI.com, a personalized AI sleep companion, today announced the launch of an AI-powered sleep and emotional wellness platform, now available on both the iOS and Google Play app stores. The platform is designed to address one of modern life's most persistent challenges: the growing disconnect between how people live and how they sleep....
Datasea Reports Second Fiscal Quarter 2026 Results
Gross Profit Increased 284.4% Year-over-Year and Gross Margin Increases 730 Basis Points to 8.8% BEIJING, Feb. 12, 2026 /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS) ("Datasea" or the "Company"), a Nevada-based technology enterprise engaged in acoustic technologies and 5G+AI multimodal digitalization, today announced its unaudited financial results for the second fiscal quarter...
Sanyou Biopharmaceuticals Lang Guojun: Making Innovative Biologics R&D Easier for Clients Worldwide
Tagline: Empowering Global Innovative Biologics R&D through Ecosystem Strength SHANGHAI, Feb. 12, 2026 /PRNewswire/ -- On February 8, at the 2026 China New Drug Source Innovation Forum in Shanghai, Lang Guojun, Founder & CEO of Sanyou Biopharmaceuticals, shared the story of a vision that began ten years ago. A decade ago, China's biopharmaceutical innovation ecosystem was still taking shape....
Ubie Announces Collaboration to Reinvent the Healthcare Digital Front Door
Ubie and Mayo Clinic collaborate with the goal of delivering a unified, AI-powered chat and voice platform to streamline healthcare access, reduce complexity and offer a best-in-class patient experience Natural conversations, instant answers, and a seamless triage-to-booking flow will drive first-contact resolution, self-scheduling and patient satisfaction scores NEW...
Clinigen Announces World-First Pharmaceutical Approval for Prolacta Bioscience’s PreemieFort® Enteral Solution, Human Milk-Based Product in Japan
Clinigen obtained approval for Prolacta's "PreemieFort® Enteral Solution", a human milk-based fortifier, as an approved pharmaceutical product in Japan indicated for the "Nutritional management of neonates and infants presenting with weight gain failure such as very low birth weight (VLBW) infants." The approval was supported by data from the pivotal Japan-based JASMINE Phase III clinical trial, a randomised,...
First clinical success! Yuanhua Tech, with its orthopaedic surgical robot with originally developed HX Orthopaedic-Specific Robotic Arm, breaks into the high-end medical equipment market
HONG KONG, Feb. 12, 2026 /PRNewswire/ -- On February 11, the orthopaedic surgical robot with originally developed HX Orthopaedic-Specific Robotic Arm, which was 100% homemade by Yuanhua Robotics, Perception and AI Technologies Ltd. (hereinafter referred to as "Yuanhua Tech"), saw its first clinical success at West China Hospital of Sichuan University. This milestone achievement signifies that the domestically produced high-end...
EDAN Connects Clinical Practice and Innovation at 2026 WHX Dubai and WHX Labs Dubai
DUBAI, UAE, Feb. 12, 2026 /PRNewswire/ -- Edan Instruments, Inc. (300206.SZ) participated in WHX Dubai (Formerly Arab Health) and WHX Labs Dubai (Formerly Medlab Middle East), presenting a comprehensive portfolio of medical solutions across multiple clinical disciplines. With an expected attendance of over 235,000 visitors at WHX Dubai and 35,000 at...
